Grufity logoGrufity logo
StocksFundsSearch Filings

Neogenomics Inc Stock Research

NEO

17.28USD-0.09(-0.52%)Market Closed

Market Summary

USD17.28-0.09
Market Closed
-0.52%

NEO Alerts

NEO Stock Price

NEO RSI Chart

NEO Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-17.59

Price/Sales (Trailing)

4.17

EV/EBITDA

-18.89

Price/Free Cashflow

-26.86

NEO Price/Sales (Trailing)

NEO Profitability

EBT Margin

-31.26%

Return on Equity

-14.45%

Return on Assets

-8.29%

Free Cashflow Yield

-3.72%

NEO Fundamentals

NEO Revenue

Revenue (TTM)

529.8M

Revenue Y/Y

17.11%

Revenue Q/Q

-1.07%

NEO Earnings

Earnings (TTM)

-125.6M

Earnings Y/Y

37.67%

Earnings Q/Q

-35.74%

Price Action

52 Week Range

6.0020.54
(Low)(High)

Last 7 days

-3.7%

Last 30 days

21.1%

Last 90 days

10.1%

Trailing 12 Months

121.0%

NEO Financial Health

Current Ratio

6.73

Debt/Equity

0.51

Debt/Cashflow

-0.14

NEO Investor Care

Shares Dilution (1Y)

1.99%

Peers (Alternatives to Neogenomics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
230.7B
43.8B
-5.06% -2.55%
33.15
5.14
6.53% -9.94%
36.6B
14.5B
3.00% -2.89%
34.72
2.53
3.29% -2.22%
14.0B
3.4B
-14.52% -17.83%
43.23
4.13
13.67% -65.23%
10.0B
4.1B
3.89% -12.79%
20.1
2.44
12.73% 17.48%
MID-CAP
6.2B
1.6B
-2.93% 52.95%
24.09
3.96
28.83% 28.57%
4.3B
5.4B
9.59% -41.20%
28.88
0.79
1.37% -38.84%
3.6B
272.8M
-0.03% -1.18%
-23.88
13.15
3.56% -34.35%
2.2B
529.8M
21.13% 120.99%
-17.59
4.17
9.02% -252.50%
SMALL-CAP
718.9M
-
15.32% -1.54%
-13.63
291.16
-34.21% -22.02%
306.6M
23.2M
6.19% -3.23%
12.35
13.19
-45.75% 126.39%
170.9M
-
-71.28% -88.95%
-0.25
2.64
22.40% -42.61%
106.8M
77.3M
6.72% -15.88%
-9.98
1.38
10.46% 61.07%
90.7M
68.7M
-11.82% -52.10%
-0.8
1.32
-13.98% -40.40%

Financials for Neogenomics

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue3.9%529,779,000509,728,000496,755,000489,313,000485,965,000
Gross Profit8.8%204,478,000187,896,000176,328,000174,674,000183,718,000
Operating Expenses-0.1%345,146,000345,519,000349,135,000347,684,000339,393,000
  S&GA Expenses-0.1%67,281,00067,321,00066,096,00064,991,00065,144,000
  R&D Expenses-1.0%30,008,00030,326,00032,164,00032,261,00027,130,000
EBITDA12.3%-122,464,000-139,670,000-122,854,000-9,986,000-
EBITDA Margin14.6%-0.24-0.28-0.25-0.02-
Earnings Before Taxes12.2%-139,901,000-159,342,000-178,022,000-161,568,000-47,099,000
EBT Margin12.8%-0.31-0.36-0.33-0.10-
Interest Expenses-63.0%1,506,0004,073,0005,230,0005,206,000-
Net Income12.9%-125,637,000-144,250,000-163,322,000-146,818,000-35,642,000
Net Income Margin13.9%-0.28-0.33-0.30-0.07-
Free Cahsflow19.6%-96,884,000-120,428,000-119,056,000-114,503,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-1.8%1,7091,7401,7561,7921,830
  Current Assets-3.4%585605603622651
    Cash Equivalents4.7%276263266284306
  Inventory0.6%24.0024.0024.0022.0024.00
  Net PPE0.3%103102107111109
  Goodwill0%523523523527527
Liabilities-1.0%735742743749755
  Current Liabilities-3.7%87.0090.0085.0083.0082.00
Shareholder's Equity-2.4%9749981,0131,0441,075
  Retained Earnings-19.4%-189-159-136-99.55-64.24
  Additional Paid-In Capital0.5%1,1671,1611,1541,1471,142
Accumulated Depreciation5.3%139132125123116
Shares Outstanding2.5%127124127126125
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations24.8%-49,645-65,993-82,084-73,579-57,973
  Share Based Compensation-29.8%17,32724,67230,07131,02831,908
Cashflow From Investing2261.1%12,207517-8,003-18,491-465,627
Cashflow From Financing-39.5%7,15111,82912,4872,808206,407

Risks for NEO

What is the probability of a big loss on NEO?

99.2%


Probability that Neogenomics stock will be more than 20% underwater in next one year

66.2%


Probability that Neogenomics stock will be more than 30% underwater in next one year.

30%


Probability that Neogenomics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NEO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Neogenomics was unfortunately bought at previous high price.

Drawdowns

Returns for NEO

Cumulative Returns on NEO

17.0%


10-Year Cumulative Returns

10.5%


7-Year Cumulative Returns

8.4%


5-Year Cumulative Returns

-14.9%


3-Year Cumulative Returns

What are the long-term rolling returns for NEO?

FIve years rolling returns for Neogenomics.

Annualized Returns

Which funds bought or sold NEO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
ROYCE & ASSOCIATES LP
reduced
-5.65
3,431,510
7,844,080
0.08%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-21.47
5,483,450
16,911,400
0.01%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
unchanged
-
222,000
1,935,000
-%
2023-05-18
JPMORGAN CHASE & CO
reduced
-20.38
6,958,000
20,865,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
added
112
3,369,000
4,488,000
0.01%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
added
12.83
704,000
3,526,000
-%
2023-05-17
Sunbelt Securities, Inc.
reduced
-91.72
-224,932
42,141
0.01%
2023-05-17
Advisory Services Network, LLC
unchanged
-
32,843
69,988
-%
2023-05-17
Thrivent Financial for Lutherans
reduced
-3.39
982,000
2,179,000
-%
2023-05-16
Rockefeller Capital Management L.P.
added
0.47
447,000
607,000
-%

1–10 of 35

Latest Funds Activity

Are funds buying NEO calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own NEO
No. of Funds

Neogenomics News

Best Stocks
Chicago Hedge Fund Increases Stake in Florida-based Medical ....
Best Stocks,
47 hours ago
Best Stocks
Zacks Investment Research
Stansberry Research
The War Hedge Worth Thinking About Today.
Stansberry Research,
15 days ago

Schedule 13G FIlings of Neogenomics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
artisan partners limited partnership
0.0%
10
SC 13G/A
Feb 09, 2023
vanguard group inc
10.83%
13,674,745
SC 13G/A
Feb 09, 2023
brown advisory inc
5%
6,337,008
SC 13G
Feb 06, 2023
wellington management group llp
0.00%
0
SC 13G/A
Jan 23, 2023
blackrock inc.
17.4%
21,932,623
SC 13G/A
Feb 04, 2022
wellington management group llp
8.99%
11,069,283
SC 13G
Feb 04, 2022
artisan partners limited partnership
6.3%
7,732,355
SC 13G
Jan 27, 2022
blackrock inc.
15.7%
19,328,254
SC 13G/A
Jan 26, 2022
blackrock inc.
15.7%
19,328,254
SC 13G
Feb 10, 2021
vanguard group inc
10.06%
11,167,578
SC 13G/A

NEO Fair Value

Recent SEC filings of Neogenomics

View All Filings
Date Filed Form Type Document
May 24, 2023
3
Insider Trading
May 24, 2023
4
Insider Trading
May 17, 2023
8-K
Current Report
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 15, 2023
4
Insider Trading
May 09, 2023
10-Q
Quarterly Report

Latest Insider Trading transactions for NEO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-22
TETRAULT LYNN A.
acquired
17,481
11.6
1,507
-
2023-05-01
Olivo Alicia C
sold (taxes)
-
-
-662
general counsel
2023-04-01
Kulkarni Shashikant
sold (taxes)
-
-
-3,759
chief scientific officer
2023-03-02
Dieter Cynthia J
sold (taxes)
-
-
-117
chief accounting officer
2023-03-01
Dieter Cynthia J
sold (taxes)
-
-
-880
chief accounting officer
2023-01-01
Harris Melody
acquired
-
-
108,225
president, enterprise ops
2022-12-31
Sikri Vishal
acquired
1,584
7.04
225
president, pharma services
2022-12-31
Dieter Cynthia J
sold (taxes)
-
-
-959
chief accounting officer
2022-12-05
Sherman Jeffrey Scott
acquired
-
-
133,809
chief financial officer
2022-12-01
Stone Warren
acquired
-
-
89,206
president, clinical services

1–10 of 50

Lynn A. Tetrault
2000
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Income Statement

2023-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Total net revenue$ 137,220$ 117,169
COST OF REVENUE82,40678,937
GROSS PROFIT54,81438,232
Operating expenses:  
General and administrative61,54966,248
Research and development7,3957,713
Sales and marketing16,25916,299
Restructuring charges4,6840
Total operating expenses89,88790,260
LOSS FROM OPERATIONS(35,073)(52,028)
Interest (income) expense, net(1,467)1,301
Other expense (income), net114(168)
Loss before taxes(33,720)(53,161)
Income tax benefit(2,925)(3,753)
NET LOSS$ (30,795)$ (49,408)
NET LOSS PER SHARE  
Basic (in dollars per share)$ (0.25)$ (0.40)
Diluted (in dollars per share)$ (0.25)$ (0.40)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING  
Basic (in shares)125,026123,630
Diluted (in shares)125,026123,630
Clinical Services  
Total net revenue$ 114,869$ 98,791
COST OF REVENUE67,29265,267
GROSS PROFIT47,57733,524
Pharma Services  
Total net revenue22,35118,378
COST OF REVENUE15,11413,670
GROSS PROFIT$ 7,237$ 4,708

NEO Balance Sheet

2023-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 275,609$ 263,180
Marketable securities, at fair value142,306174,809
Accounts receivable, net118,842119,711
Inventories24,43224,277
Prepaid assets16,18515,237
Other current assets7,6228,077
Total current assets584,996605,291
Property and equipment (net of accumulated depreciation of $138,863 and $131,930, respectively)102,845102,499
Operating lease right-of-use assets93,78496,109
Intangible assets, net399,477408,260
Goodwill522,766522,766
Other assets5,3065,109
Total non-current assets1,124,1781,134,743
Total assets1,709,1741,740,034
Current liabilities  
Accounts payable22,71220,510
Accrued compensation32,89140,141
Accrued expenses and other liabilities17,96415,070
Current portion of equipment financing obligations3870
Current portion of operating lease liabilities6,9346,584
Pharma contract liabilities6,0677,557
Total current liabilities86,60689,932
Long-term liabilities  
Convertible senior notes, net536,037535,322
Operating lease liabilities67,31968,952
Deferred income tax liabilities, net31,71534,750
Other long-term liabilities13,03513,055
Total long-term liabilities648,106652,079
Total liabilities734,712742,011
Commitments and contingencies (Note 11)
Stockholders’ equity  
Common stock, $0.001 par value, (250,000,000 shares authorized; 127,200,491 and 126,913,992 shares issued and outstanding, respectively)127127
Additional paid-in capital1,167,0511,160,882
Accumulated other comprehensive loss(2,834)(3,899)
Accumulated deficit(189,882)(159,087)
Total stockholders’ equity974,462998,023
Total liabilities and stockholders’ equity$ 1,709,174$ 1,740,034